Physician profile
Vida Umstead
NPI 1366471914
$864.45
in general payments reported to CMS, 2019-2025
13 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5.57 · 2022: $78.46 · 2023: $338 · 2024: $291 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $317.40 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Viiv Healthcare Company | $131.76 | 2022-2024 | Apretude |
| Lilly USA, LLC | $84.18 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $56.33 | 2024-2025 | Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $49.57 | 2024-2025 | |
| Dynavax Technologies Corporation | $39.32 | 2024 | Heplisav-B |
| Abbott Laboratories | $38.87 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $37.55 | 2023-2025 | |
| Exact Sciences Corporation | $36.15 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $28.14 | 2023-2024 | Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $22.25 | 2023 | Shingrix |
| Astellas Pharma US INC | $17.36 | 2024 | Veozah |
| Genentech USA, INC. | $5.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vida Umstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.